ADBM Indications
Low-dose topical administration of ADBM in a biofilm compromised 12-day infected animal model has shown that it is stimulating both tissue granulation (new microscopic blood vessels and connective tissues) and closure of the epithelial gap (the margins of the wound), both of which are the FDA’s two primary endpoints for wound healing. There is no known competitor to ADBM as a drug that destroys biofilms, enhances wound closure, and does not contribute to antibiotic resistance.
In conjunction with Johns Hopkins Medical School’s Center for Tuberculosis Research, Liberty’s scientists are stressing ADBM’s capabilities to destroy biofilms formed by Mycobacterium lung infections, to include those formed by Mycobacterium Tuberculosis (TB). Initial preclinical work has demonstrated ADBM’s promise as a candidate therapeutic for use in TB patients; a program of global importance given that TB kills more people than any other infectious disease (circa 1.8 million people annually) and continues to demonstrate increasing resistance to mainline antibiotic therapies. In vivo testing of ADBM in TB models will begin in Q3 of 2019.
Low-dose topical administration of ADBM in a biofilm compromised 12-day infected animal model has shown that it is stimulating both tissue granulation (new microscopic blood vessels and connective tissues) and closure of the epithelial gap (the margins of the wound), both of which are the FDA’s two primary endpoints for wound healing. There is no known competitor to ADBM as a drug that destroys biofilms, enhances wound closure, and does not contribute to antibiotic resistance.
In conjunction with Johns Hopkins Medical School’s Center for Tuberculosis Research, Liberty’s scientists are stressing ADBM’s capabilities to destroy biofilms formed by Mycobacterium lung infections, to include those formed by Mycobacterium Tuberculosis (TB). Initial preclinical work has demonstrated ADBM’s promise as a candidate therapeutic for use in TB patients; a program of global importance given that TB kills more people than any other infectious disease (circa 1.8 million people annually) and continues to demonstrate increasing resistance to mainline antibiotic therapies. In vivo testing of ADBM in TB models will begin in Q3 of 2019.
Diabetic Foot Ulcers
ADBM is being developed to treat a range of challenging diseases and indications, with initial emphasis on chronically infected Diabetic Foot Ulcers (DFUs), an indication for which the U.S. alone spends $13 billion a year treating.
ADBM is being developed to treat a range of challenging diseases and indications, with initial emphasis on chronically infected Diabetic Foot Ulcers (DFUs), an indication for which the U.S. alone spends $13 billion a year treating.
|
Impact
A person with Diabetes is thirty times more likely to have a lower limb amputation than the average non-diabetic. With poor circulation and neuropathy, a simple stubbed toe or blister can turn into the image on the right. One small wound can be life changing or even deadly. After a lower limb amputation, one is 80% more likely to die within the following five year period. Hear more from organizations that are fighting to save people with diabetes from unnecessary amputations: 
Leading health organizations believe the way in which we discuss Diabetes needs to change. The APMA shows that the economic impact is $245B a year in the US |
|
|
Diabetes lower limb complications ranks number six in the Causes of Global Disability according to Diabetic Foot Australia [cite]
|
![[cite]](https://diabeticfootaustralia.org/wp-content/uploads/Comparing-the-global-causes-of-disability.png){kind=link}
Liberty Biosecurity is a privately-owned life sciences and a founding company in the EdenRoc Sciences family of companies. Liberty develops solutions to the most challenging problems in biology, national security, and human health. Liberty is headquartered in Virginia with laboratories and offices in Massachusetts, Florida, Thailand and Australia.